title: Costimulation Blockade in Kidney Transplantation: An Update.
abstract: In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)-based therapy remains the cornerstone of immunosuppression. However, long-term use of CNIs is associated with some degree of nephrotoxicity. This has led to exploring the blockade of some costimulation pathways as an efficient immunosuppressive tool instead of using CNIs. The only agent already in clinical use and approved by the health authorities for kidney transplant patients is belatacept (Nulojix), a fusion protein that interferes with cytotoxic T lymphocyte-associated protein 4. Belatacept has been demonstrated to be as efficient as cyclosporine-based immunosuppression and is associated with significantly better renal function, that is, no nephrotoxicity. However, in the immediate posttransplant period, significantly more mild/moderate episodes of acute rejection have been reported, favored by the fact that cytotoxic T lymphocyte-associated protein pathway has an inhibitory effect on the alloimmune response; thereby its inhibition is detrimental in this regard. This has led to the development of antibodies that target CD28. The most advanced is FR104, it has shown promise in nonhuman primate models of autoimmune diseases and allotransplantation. In addition, research into blocking the CD40-CD154 pathway is underway. A phase II study testing ASK1240, that is, anti-CD40 antibody has been completed, and the results are pending.
authors.affiliation: 1 Clinique Universitaire de Néphrologie, Unité de Transplantation Rénale, CHU Grenoble, France. 2 Université Joseph Fourier, Grenoble, France. 3 UniversitéToulouse III Paul Sabatier, Toulouse, France. 4 INSERM U563, IFR-BMT, CHU Purpan, Toulouse, France.
authors.forename: Paolo
authors.initials: P
authors.lastname: Malvezzi
authors.forename: Thomas
authors.initials: T
authors.lastname: Jouve
authors.forename: Lionel
authors.initials: L
authors.lastname: Rostaing
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018122:B7-1 Antigen / Q000037:antagonists & inhibitors; D051940:B7-2 Antigen / Q000037:antagonists & inhibitors; D018106:CD28 Antigens / Q000037:antagonists & inhibitors*; D019013:CD40 Antigens / Q000037:antagonists & inhibitors*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D065095:Calcineurin Inhibitors / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; D019013:CD40 Antigens; D060908:CTLA-4 Antigen; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C586087:bleselumab